FORUS Therapeutics is thrilled to welcome Karen Winkworth as Therapeutic Area Manager, Hematology/Oncology, GTA. Karen brings with her a proven track record of delivering superior value across therapeutic areas – including over 15 years in hematology and...
FORUS Therapeutics is delighted to welcome Chris Mitton as Therapeutic Area Manager, Hematology/Oncology, Atlantic Canada. Chris joins FORUS with over 30 years experience as a pharmaceutical professional with extensive expertise across various therapeutic areas,...
In a remarkable decision posted earlier this month, INESSS stands alone in failing to recognize the therapeutic value of XPOVIO. This despite Health Canada approval, a positive CADTH decision, Quebec clinician and patient support and positive funding recommendations...
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in PEI as of April 23rd. Please see the following links for full funding criteria: PEI Pharmacare Bulletin – Pharmacist Bulletin – April 09, 2024 We are excited about these...
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Ontario, Newfoundland and Labrador, and New Brunswick. Please see the following links for full funding criteria: Ontario: Exceptional Access Program | ontario.ca Newfoundland...
FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Nova Scotia as of October 1st. Please see the following link for full funding criteria: Nova Scotia Pharmacare News Bulletins Pharmacy Edition (novascotia.ca) We are excited...
Recent Comments